MedTrace Logo

Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata

NCT05600673 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-10-31

No results posted yet for this study

Summary

The goal of this study is to evaluate the efficacy and safety of combined CO2 fractional laser with Bimatoprost 0.03% as novel treatment of alopecia areata.

The main question to study is will the bimatoprost facilitate hair growth if added to fractional CO2 laser treatment in Alopecia areata.

Conditions

Interventions

DRUG

Bimatoprost 0.03% solution

Topical Bimatoprost 0.03% solution

DEVICE

CO2 fractional laser

CO2 fractional laser treatment

Sponsors & Collaborators

  • Ahmed Hassan Nouh MD

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2021-01-30
Completion
2021-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05600673 on ClinicalTrials.gov